Familial lipoprotein lipase deficiency (FLLD) is a rare genetic disorder characterized by insufficient activity of the enzyme lipoprotein lipase, which leads to lipid metabolism disorders. Lipoprotein lipase is responsible for processing triglycerides contained in lipoproteins such as chylomicrons and very low-density lipoproteins (VLDL). The accumulation of these lipids in the blood leads to hypertriglyceridemia, which can manifest itself with clinical symptoms such as abdominal pain, pancreatitis, and the appearance of xanthomatoses on the skin. This condition requires a special approach to diagnosis and treatment, given its genetic nature and potential complications.
History of the disease and interesting historical facts
The first mention of familial lipoprotein lipase deficiency was made in the 1970s, when researchers began to notice a link between hereditary factors and lipid metabolism disorders. In 1984, the first lipoprotein lipase mutation was associated with patients with the disease. Research in the 1990s contributed to the understanding of the mechanisms of FDLL pathogenesis, which allowed scientists to identify the associated genes and their mutations. Specific tests for lipoprotein lipase levels were developed to more accurately diagnose. Interestingly, in some communities, this disease is much more common, indicating its hereditary nature.
Epidemiology
According to current research, the prevalence of familial lipoprotein lipase deficiency varies in different populations. Data show that in some ethnic groups, such as certain Native American tribes and large genetically isolated populations, this condition may occur at a frequency of 1 in 2,000-3,000 people. At the same time, in the average population, the prevalence of FDLL is approximately 1 in 1,000,000 people, making it a rare disease. An important factor is that many patients remain undiagnosed, especially in regions with limited access to health services and laboratory tests.
Genetic predisposition to this disease
FDLL is caused by mutations in the LPL gene, located on chromosome 8. This gene codes for the enzyme lipoprotein lipase, which is responsible for breaking down triglycerides. More than 180 different mutations have been registered to date, which can lead to a complete absence of the enzyme or to its partial functional activity. Mutations can be either homozygous or heterozygous, but the most severe form of the disease, which occurs in children, is usually caused by homozygous mutations. Genetic testing can identify predisposition to the disease and provide information for genetic counseling of patients.
Risk factors for the development of this disease
The main risk factors for developing familial lipoprotein lipase deficiency are:
- Heredity: Having relatives diagnosed with FDLL significantly increases the risk of the disease.
- Certain ethnic groups: An increased incidence of the disease is observed in ethnic groups with an isolated gene pool.
- Association with other metabolic disorders: Patients with diabetes, obesity and metabolic syndrome may have a higher risk of developing complications if they have FDLL.
- Lifestyle changes: lack of physical activity and poor nutrition can worsen the condition of patients with this pathology.
Diagnosis of this disease
Diagnosis of familial lipoprotein lipase deficiency is based on a combination of clinical and laboratory methods:
- Main symptoms: The typical clinical picture is recurrent episodes of abdominal pain, pancreatitis, xanthomas and xangomas.
- Laboratory tests: the main method is to determine the level of triglycerides in the blood, which is significantly elevated in FDLL. In most cases, high values exceed 1000 mg/dL.
- Radiological examinations: Ultrasound may reveal enlargement of the liver and spleen, as well as xanthomas under the skin.
- Other diagnostics: Genetic testing can confirm the diagnosis by identifying known mutations in the LPL gene.
- Differential diagnosis: It is important to distinguish FDLL from other forms of hypertriglyceridemia, such as Chigerin syndrome or secondary hypertriglyceridemia in various diseases.
Treatment
Treatment of familial lipoprotein lipase deficiency involves a comprehensive approach aimed at reducing triglyceride levels and preventing complications:
- General treatment: A strict low-fat diet (less than 15% of total calories) is recommended, avoiding high-calorie foods, alcoholic beverages and simple carbohydrates.
- Pharmacological treatment: The main drugs are fibrates (eg, genfibrozil) and nicotinic acid, which help lower triglyceride levels.
- Surgery: In rare cases, surgery may be needed to remove xanthomas or other complications.
- Other treatments: Omega-3 triglyceride therapy may have a positive effect on blood lipid levels.
List of medications used to treat this disease
- Fibrates (genfibrozil, fasigin)
- A nicotinic acid
- Omega-3 triglycerides (omea-3 fish oil)
- Statins (in certain cases to lower total cholesterol)
- Injectable drugs (anti-PCSK9) in more complex cases
Disease monitoring
Monitoring of familial lipoprotein lipase deficiency includes regular monitoring of triglyceride levels:
- Control steps: It is recommended to check lipid levels every 3-6 months.
- Prognosis: With adequate therapy and diet, the prognosis can be favorable, but there is a risk of complications such as pancreatitis and cardiovascular problems.
- Complications: Long-term hypertriglyceridemia can lead to pancreatic damage and other systemic disorders.
Age-related features of the disease
Familial lipoprotein lipase deficiency can present at any age, but there are differences in the clinical picture:
- Childhood: Symptoms may begin in infancy and present as early episodes of pancreatitis.
- Adolescence: Adolescents are more likely to develop xanthomas and abdominal pain, which may lead to the need for more serious medical evaluation.
- Adulthood: The disease is characterized by more pronounced hypertriglyceridemia and an increased risk of cardiovascular disease.
- Old age: Older people usually have concomitant pathology, which can complicate the course of the disease.
Questions and Answers
- What is familial lipoprotein lipase deficiency? It is a genetic disorder associated with a deficiency of the enzyme lipoprotein lipase, which leads to the accumulation of triglycerides in the blood.
- What are the main symptoms of the disease? The main symptoms include abdominal pain, the appearance of xanthomas and elevated levels of triglycerides in the blood.
- Is it possible to prevent the disease? It is impossible to completely prevent FDLL, but following a low-fat diet can help prevent serious complications.
- How to diagnose the disease? Diagnosis is based on clinical features, triglyceride levels and genetic testing.
- What treatment is indicated for FDLL? Treatment involves following a strict diet and using medication to lower triglyceride levels.
Advice from Dr. Oleg Korzhikov
Dr. Oleg Korzhikov recommends that patients with familial lipoprotein lipase deficiency pay special attention to their diet and regular check-ups. It is important to monitor triglyceride levels and regularly consult a doctor if new symptoms occur. He emphasizes that a properly selected diet and strict adherence to prescribed treatment can significantly improve the quality of life. It is also worth paying attention to the family history of the disease and undergoing genetic counseling in a timely manner to assess the risks to offspring.
